Novel ideas fuel our entrepreneurial passion. With a breakthrough concept for women, we “sprouted” out of Slate Pharmaceuticals in 2011 to focus on delivering a first-in-class, first-in-disease approval for female sexual dysfunction. Sprout is the owner of flibanserin, a novel, non-hormonal treatment that has shown promise addressing hypoactive sexual desire disorder, the most common form of female sexual dysfunction. We acquired the compound from Boehringer Ingelheim.
With an updated New Drug Application filed in the spring of 2013, flibanserin is poised to potentially be the first drug approved to treat distressing low desire in women. The first drug of its kind.
For the latest news of Sprout, visit our news center.